1. /
  2. About us /
  3. Our people and structure /
  4. Our people /
  5. Bridget Draper
Our people

Dr Bridget Draper

Senior Research Officer

Taking students

Working groups

bridget.draper@burnet.edu.au
+61385062395
Dr Bridget Draper

Background

Bridget works as a Senior Research Officer in the Disease Elimination program, with a specific focus on viral hepatitis projects in low- and middle-income countries. She currently works on the TREAT-HEP Myanmar project and the HepC CUTTS project.

Bridget completed a Bachelor of Arts (International Studies) at RMIT and her honours in Health Sciences through Monash University at the Burnet Institute. Her honours project focussed on acceptability of HIV pre-exposure prophylaxis among men who have sex with men in Myanmar. In 2022, Bridget completed her PhD exploring how to provide hepatitis C testing and treatment in resource-constrained settings using implementation science and health service delivery research methods.

Her work involved evaluating hepatitis C treatment programs in specialist and primary care settings in Myanmar, including the CT2 Study and evaluation of the National Hepatitis Control Program.

Qualifications

  • 2022: Doctor of Philosophy, Monash University, Australia
  • 2015: Honours (Health Sciences), Monash University, Australia
  • 2014: Bachelor of Arts (International Studies), RMIT, Australia

Burnet publications

View 38 more
16 Jan 2024

Patients’ experience of accessing hepatitis C treatment through the Myanmar national hepatitis C treatment program: a qualitative evaluation

BMC Health Services Research

Bridget Draper, Anna L. Bowring, Jessica Howell

Open access
03 Nov 2023

The National Naloxone Reference Group: A collective voice on take‐home naloxone policy and practice in Australia

Drug and Alcohol Review

Paul Dietze, Ashleigh C. Stewart, Penny Hill, Bridget Draper, M. David Curtis, Amy Kirwan

Open access
20 Oct 2023

Cost‐effectiveness of a decentralized, community‐based “one‐stop‐shop” hepatitis C testing and treatment program in Yangon, Myanmar

JGH Open

Bridget Draper, Anna Palmer, Margaret Hellard, Nick Scott

Open access

Current projects

TREAT-HEP: community-based viral hepatitis testing and treatment project in Yangon, Myanmar

TREAT-HEP: community-based viral hepatitis testing and treatment project in Yangon, Myanmar

This project delivers hepatitis C prevention, testing and treatment services and hepatitis B testing and vaccination services.

CUTTS HepC: Catalysing uptake of under-utilised tools & treatment simplification for HepC
Open to students

CUTTS HepC: Catalysing uptake of under-utilised tools & treatment simplification for HepC

This project will generate evidence on how to improve hepatitis C prevention and care for people who inject drugs in low-and middle-income countries.

Past projects

View 1 more
The elimination of hepatitis C as a global public health threat

The elimination of hepatitis C as a global public health threat

This project addresses critical knowledge gaps in Australian and global efforts to eliminate hepatitis C as a public health threat by 2030.

Eliminate C (EC) Victoria partnership

Eliminate C (EC) Victoria partnership

A partnership aimed at increasing hepatitis C treatment uptake among people who inject drugs (PWID) using nurse-led models of care in community and prison settings.

Hepatitis C: Community Testing and Treatment (CT2)

Hepatitis C: Community Testing and Treatment (CT2)

This study examined the feasibility of a community-based testing and treatment program for hepatitis C.

View 1 more

News and features

View 5 more
Australia Awards Fellows join Burnet to improve outcomes for people with hepatitis C

Australia Awards Fellows join Burnet to improve outcomes for people with hepatitis C

New treatment pathways for hepatitis C

New treatment pathways for hepatitis C

Newly published Burnet study demonstrates the feasibility and effectiveness of simplified treatment of hepatitis C in Myanmar.

Burnet is part of global effort to prevent hepatitis C

Burnet is part of global effort to prevent hepatitis C

Burnet Institute is a key partner in a new global harm reduction program aiming to reduce the impact of hepatitis C among at-risk groups thanks to funding from global health agency Unitaid.

View 5 more
On this page